Therapies for Chronic Allograft Rejection.

Front Pharmacol · 2021 · PMC8082459 · PMID 33935762

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

The use of belimumab, a BAFF inhibitor, showed a trend to reduce naïve B cells, circulating plasmablasts, and memory B cells in adult KT recipients ( Banham et al., 2018 ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.